SAGE - Sage Therapeutics, Inc.
145.49 0.00 (0.00%)
After hours: 5:00PM EDT
| Previous close | 148.01 |
| Open | 150.02 |
| Bid | 143.00 x 100 |
| Ask | 146.98 x 100 |
| Day's range | 142.15 - 151.65 |
| 52-week range | 59.57 - 195.97 |
| Volume | 613,446 |
| Avg. volume | 570,164 |
| Market cap | 6.66B |
| Beta | 3.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.09 |
| Earnings date | 7 Aug 2017 - 11 Aug 2017 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 206.29 |
- Business Wire•12 hours ago
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, an intravenous formulation of brexanolone (SAGE-547), for the treatment of postpartum depression (PPD). Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates intended to treat serious conditions, including increased interaction and guidance from the FDA.
- Motley Fool•3 days ago
Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
Learn which stock fell on fears about merger and acquisition prospects.
- Business Wire•6 days ago
Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
Sage Therapeutics a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that data from clinical studies of its proprietary i.v.
- Zacks•18 days ago
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
- Business Wire•19 days ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on April 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 162,000 shares of its common stock to twenty new employees under Sage’s 2016 Inducement Equity ...
CNBC•26 days agoSage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
Sage Therapeutics has to balance two competing interests when it comes to pricing its postpartum depression drug, CEO Jeff Jonas says.
CNBC•last monthMartin Shkreli's legacy: Putting a 'fine point' on the drug pricing debate
Martin Shkreli's actions involving pharmaceutical pricing have had a long-lasting impact.
- Investor's Business Daily•2 months ago
Biotech Jumps After Rival Pushes Back Depression Drug Tests
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
- Motley Fool•2 months ago
Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
The biopharma's slide continues -- for good reason this time.
- Business Wire•2 months ago
Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Sage will participate in a fireside chat presentation at the Cowen & Co.
- Business Wire•2 months ago
Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update
Sage Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
- GlobeNewswire•2 months ago
Research Report Identifies Advanced Disposal Services, Opus Bank, Anworth Mortgage Asset, Exelon, Newell Brands, and Sage Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced ...
- Business Wire•2 months ago
Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, February 22, 2018 at 8:00 A.M.
- Business Wire•2 months ago
Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Sage will participate in a fireside chat presentation at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 1:30 P.M.
- Business Wire•2 months ago
Sage Therapeutics Prices Public Offering of Common Stock
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the pricing of an underwritten public offering of 3,506,098 shares of its common stock at a public offering price of $164.00 per share.
- Business Wire•2 months ago
Sage Therapeutics Announces Proposed Public Offering of Common Stock
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that it has commenced an underwritten public offering of $575.0 million of its common stock.
- Business Wire•2 months ago
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the U.S.
- Business Wire•3 months ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on February 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 113,000 shares of its common stock to sixteen new employees under Sage’s 2016 Inducement Equity ...
- Investor's Business Daily•3 months ago
Sage Therapeutics Just Popped To A Record High — Here's Why
Sage popped to a record high Wednesday after its depression drug also showed promise in an insomnia trial.
- Business Wire•3 months ago
Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results from a Phase 1/2, double-blind, placebo-controlled study of SAGE-217 in the treatment of healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.
- Motley Fool•3 months ago
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
These small biotechs could be prime buyout candidates in 2018.
- Business Wire•3 months ago
Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that in a corporate presentation at the 36th Annual J.P.
- Business Wire•4 months ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that, on January 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 144,800 shares of its common stock to fifteen new employees under Sage’s 2016 Inducement Equity ...
- Business Wire•4 months ago
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company is scheduled to present at the J.P.
